Analysts Set Targets Across Five Biotech Stocks
Analysts Set Targets Across Five Biotech Stocks
Anonymous
Key Points
1
X4 Pharmaceuticals received an “overweight” rating and an $11 price objective from Wells Fargo, while Leerink Partners initiated coverage with an “outperform” rating and a $12 target.
2
Pyxis Oncology’s price targets showed a wide range of recent analyst views: Wells Fargo raised its target to $19, while Leerink Partners cut its target to $7; Wedbush and HC Wainwright both set targets of $8.
3
Obsidian Therapeutics is described as a clinical-stage biopharmaceutical company using protein-regulation technology to develop engineered tumor-infiltrating lymphocyte therapies for solid tumors.
4
Citigroup’s $5 price target for Acumen Pharmaceuticals represented a stated potential upside of 79.53% from the company’s share price at the time of the report.
5
Odyssey Therapeutics reported a quarterly loss of $1.74 per share, and analysts projected a full-year loss of $5.99 per share; JPMorgan raised its target from $26 to $29 while retaining an overweight rating.
Analysts are backing five biotech stocks with cautiously bullish views, assigning each a consensus "Moderate Buy" rating despite scattered sell and hold calls WatchlistNews. The group includes X4 Pharmaceuticals at an $11.25 average target, Pyxis Oncology at $8.75, Obsidian Therapeutics at $42.50, Acumen Pharmaceuticals at $7, and Odyssey Therapeutics at $35.75. Together, they paint a mixed picture of opportunity in early-stage therapies and clinical-stage platforms.
X4 Pharmaceuticals leads the group on earnings strength, beating both profit and revenue estimates in its latest quarter TickerReport. Odyssey faces near-term losses of $5.99 per share annually, though JPMorgan just raised its target to $29. Acumen's stock offers potential 79.53% upside at analyst targets, even after posting a larger-than-expected quarterly loss GuruFocus.
X4 Pharma Beats Estimates With Strong Analyst Support
X4 Pharmaceuticals commands the most bullish consensus among the five, with four buy ratings out of six analysts covering the stock WatchlistNews. Wells Fargo assigned an "overweight" rating with an $11 price target, while Leerink Partners initiated coverage with an "outperform" rating and a higher $12 target. The company's latest quarterly results exceeded Wall Street expectations on both earnings and revenue, validating analyst optimism TickerReport.
Pyxis Oncology Split Between Bullish and Cautious Views
Pyxis Oncology displays the widest analyst disagreement of the group, with price targets ranging from $7 to $19 GuruFocus. Wells Fargo lifted its target to $19, betting on upside potential. But Leerink Partners cut its target to just $7, signaling skepticism. Wedbush and HC Wainwright both landed on middle ground at $8 per share TickerReport.
The split reflects Pyxis's recent miss on earnings estimates, leaving analysts divided on the company's near-term execution. The $8.75 average target masks this underlying disagreement GuruFocus.
Obsidian's Engineered Cell Therapy Draws Clinical Scrutiny
Obsidian Therapeutics, a clinical-stage company, is being evaluated on its engineered tumor-infiltrating lymphocyte (TIL) cell-therapy platform WatchlistNews. Six analysts set a $42.50 consensus price target, betting that the company's protein-regulation technology can deliver treatments for solid tumors. The therapy approach remains unproven in late-stage trials, making this a higher-risk, higher-reward thesis GuruFocus.
Acumen Maintains Buy Calls Despite Larger-Than-Expected Losses
Acumen Pharmaceuticals posted a larger-than-expected quarterly loss but still drew a buy rating and a $5 price target from Citigroup GuruFocus. The target implies 79.53% potential upside from the stock's price at the time of the report. This suggests analysts see value in the company's pipeline despite near-term red ink. The $7 consensus target across all analysts reflects cautious optimism TickerReport.
Odyssey Faces Annual Losses but Draws JPMorgan Price Hike
Odyssey Therapeutics reported a quarterly loss of $1.74 per share and faces projected full-year losses of $5.99 per share GuruFocus. Yet JPMorgan recently raised its price target from $26 to $29, keeping an overweight rating on the stock. Analysts emphasize the company's precision-medicine programs targeting immune-mediated diseases and cancer as long-term growth drivers WatchlistNews.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
11
Reach
28
A
AnonymousAuthor
